Selected research
Industry Research
Stem Cell Therapy for Osteoarthritis Industry Research Report 2026
Market perspective
The global Stem Cell Therapy for Osteoarthritis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Stem Cell Therapy for Osteoarthritis market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Stem Cell Therapy for Osteoarthritis market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Stem Cell Therapy for Osteoarthritis market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Stem Cell Therapy for Osteoarthritis include Xintela AB, UCI Health, Theracell Advanced Biotechnology, Stempeutics, Regeneus, Nature Cell, Medipost, Magellan and CellTex Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Stem Cell Therapy for Osteoarthritis market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Stem Cell Therapy for Osteoarthritis.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Stem Cell Therapy for Osteoarthritis Market by Company
Xintela AB
UCI Health
Theracell Advanced Biotechnology
Stempeutics
Regeneus
Nature Cell
Medipost
Magellan
CellTex Therapeutics
Cells for Cells
AbelZeta Pharma
Stem Cell Therapy for Osteoarthritis Segment by Type
Fat Cell
Bone Marrow Cell
Others
Stem Cell Therapy for Osteoarthritis Segment by Application
Primary Osteoarthritis
Secondary Osteoarthritis
Stem Cell Therapy for Osteoarthritis Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Stem Cell Therapy for Osteoarthritis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Stem Cell Therapy for Osteoarthritis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Stem Cell Therapy for Osteoarthritis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Stem Cell Therapy for Osteoarthritis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fat Cell
- Bone Marrow Cell
- Others
Applications
- Primary Osteoarthritis
- Secondary Osteoarthritis
Companies covered
- Xintela AB
- UCI Health
- Theracell Advanced Biotechnology
- Stempeutics
- Regeneus
- Nature Cell
- Medipost
- Magellan
- CellTex Therapeutics
- Cells for Cells
- AbelZeta Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Stem Cell Therapy for Osteoarthritis by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fat Cell
- 2.2.3 Bone Marrow Cell
- 2.2.4 Others
- 2.3 Stem Cell Therapy for Osteoarthritis by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Primary Osteoarthritis
- 2.3.3 Secondary Osteoarthritis
- 2.4 Assumptions and Limitations
3 Stem Cell Therapy for Osteoarthritis Breakdown Data by Type
- 3.1 Global Stem Cell Therapy for Osteoarthritis Historic Market Size by Type (2021-2026)
- 3.2 Global Stem Cell Therapy for Osteoarthritis Forecasted Market Size by Type (2027-2032)
4 Stem Cell Therapy for Osteoarthritis Breakdown Data by Application
- 4.1 Global Stem Cell Therapy for Osteoarthritis Historic Market Size by Application (2021-2026)
- 4.2 Global Stem Cell Therapy for Osteoarthritis Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Stem Cell Therapy for Osteoarthritis Market Perspective (2021-2032)
- 5.2 Global Stem Cell Therapy for Osteoarthritis Growth Trends by Region
- 5.2.1 Global Stem Cell Therapy for Osteoarthritis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Stem Cell Therapy for Osteoarthritis Historic Market Size by Region (2021-2026)
- 5.2.3 Stem Cell Therapy for Osteoarthritis Forecasted Market Size by Region (2027-2032)
- 5.3 Stem Cell Therapy for Osteoarthritis Market Dynamics
- 5.3.1 Stem Cell Therapy for Osteoarthritis Industry Trends
- 5.3.2 Stem Cell Therapy for Osteoarthritis Market Drivers
- 5.3.3 Stem Cell Therapy for Osteoarthritis Market Challenges
- 5.3.4 Stem Cell Therapy for Osteoarthritis Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Stem Cell Therapy for Osteoarthritis Players by Revenue
- 6.1.1 Global Top Stem Cell Therapy for Osteoarthritis Players by Revenue (2021-2026)
- 6.1.2 Global Stem Cell Therapy for Osteoarthritis Revenue Market Share by Players (2021-2026)
- 6.2 Global Stem Cell Therapy for Osteoarthritis Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Stem Cell Therapy for Osteoarthritis Head Office and Area Served
- 6.4 Global Stem Cell Therapy for Osteoarthritis Players, Product Type & Application
- 6.5 Global Stem Cell Therapy for Osteoarthritis Manufacturers Established Date
- 6.6 Global Stem Cell Therapy for Osteoarthritis Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Stem Cell Therapy for Osteoarthritis Market Size (2021-2032)
- 7.2 North America Stem Cell Therapy for Osteoarthritis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Stem Cell Therapy for Osteoarthritis Market Size by Country (2021-2026)
- 7.4 North America Stem Cell Therapy for Osteoarthritis Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Stem Cell Therapy for Osteoarthritis Market Size (2021-2032)
- 8.2 Europe Stem Cell Therapy for Osteoarthritis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Stem Cell Therapy for Osteoarthritis Market Size by Country (2021-2026)
- 8.4 Europe Stem Cell Therapy for Osteoarthritis Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Stem Cell Therapy for Osteoarthritis Market Size (2021-2032)
- 9.2 Asia-Pacific Stem Cell Therapy for Osteoarthritis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Stem Cell Therapy for Osteoarthritis Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Stem Cell Therapy for Osteoarthritis Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Stem Cell Therapy for Osteoarthritis Market Size (2021-2032)
- 10.2 South America Stem Cell Therapy for Osteoarthritis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Stem Cell Therapy for Osteoarthritis Market Size by Country (2021-2026)
- 10.4 South America Stem Cell Therapy for Osteoarthritis Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Stem Cell Therapy for Osteoarthritis Market Size (2021-2032)
- 11.2 Middle East & Africa Stem Cell Therapy for Osteoarthritis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Stem Cell Therapy for Osteoarthritis Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Stem Cell Therapy for Osteoarthritis Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Xintela AB
- 12.1.1 Xintela AB Company Information
- 12.1.2 Xintela AB Business Overview
- 12.1.3 Xintela AB Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.1.4 Xintela AB Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.1.5 Xintela AB Recent Developments
- 12.2 UCI Health
- 12.2.1 UCI Health Company Information
- 12.2.2 UCI Health Business Overview
- 12.2.3 UCI Health Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.2.4 UCI Health Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.2.5 UCI Health Recent Developments
- 12.3 Theracell Advanced Biotechnology
- 12.3.1 Theracell Advanced Biotechnology Company Information
- 12.3.2 Theracell Advanced Biotechnology Business Overview
- 12.3.3 Theracell Advanced Biotechnology Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.3.4 Theracell Advanced Biotechnology Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.3.5 Theracell Advanced Biotechnology Recent Developments
- 12.4 Stempeutics
- 12.4.1 Stempeutics Company Information
- 12.4.2 Stempeutics Business Overview
- 12.4.3 Stempeutics Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.4.4 Stempeutics Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.4.5 Stempeutics Recent Developments
- 12.5 Regeneus
- 12.5.1 Regeneus Company Information
- 12.5.2 Regeneus Business Overview
- 12.5.3 Regeneus Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.5.4 Regeneus Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.5.5 Regeneus Recent Developments
- 12.6 Nature Cell
- 12.6.1 Nature Cell Company Information
- 12.6.2 Nature Cell Business Overview
- 12.6.3 Nature Cell Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.6.4 Nature Cell Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.6.5 Nature Cell Recent Developments
- 12.7 Medipost
- 12.7.1 Medipost Company Information
- 12.7.2 Medipost Business Overview
- 12.7.3 Medipost Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.7.4 Medipost Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.7.5 Medipost Recent Developments
- 12.8 Magellan
- 12.8.1 Magellan Company Information
- 12.8.2 Magellan Business Overview
- 12.8.3 Magellan Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.8.4 Magellan Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.8.5 Magellan Recent Developments
- 12.9 CellTex Therapeutics
- 12.9.1 CellTex Therapeutics Company Information
- 12.9.2 CellTex Therapeutics Business Overview
- 12.9.3 CellTex Therapeutics Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.9.4 CellTex Therapeutics Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.9.5 CellTex Therapeutics Recent Developments
- 12.10 Cells for Cells
- 12.10.1 Cells for Cells Company Information
- 12.10.2 Cells for Cells Business Overview
- 12.10.3 Cells for Cells Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.10.4 Cells for Cells Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.10.5 Cells for Cells Recent Developments
- 12.11 AbelZeta Pharma
- 12.11.1 AbelZeta Pharma Company Information
- 12.11.2 AbelZeta Pharma Business Overview
- 12.11.3 AbelZeta Pharma Revenue in Stem Cell Therapy for Osteoarthritis Business (2021-2026)
- 12.11.4 AbelZeta Pharma Stem Cell Therapy for Osteoarthritis Product Portfolio
- 12.11.5 AbelZeta Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst